This review article discusses the role of testosterone in treating hypoactive sexual desire disorder (HSDD) in postmenopausal women, particularly those who have undergone surgical menopause. Testosterone therapy (300 µg/day transdermally) was found to improve sexual desire and arousal with minimal side effects. However, the long-term risks of testosterone therapy remain
